Drug intelligence / Profile preview

hsa-miR-6752-5p inhibitor

Development stage: Preclinical
Modality: Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics

Overview

hsa-miR-6752-5p inhibitor is a type of RNA therapy designed to block the activity of the microRNA hsa-miR-6752-5p. MicroRNAs (miRNAs) are small non-coding RNAs that regulate gene expression. This specific miRNA was investigated for its potential role in regulating human telomerase reverse transcriptase (hTERT), a key component of telomerase, as a strategy to inhibit telomerase activity for cancer treatment. While hsa-miR-6752-5p was identified as a miRNA that could interact with hTERT mRNA, a study indicated that its inhibition did not profoundly affect hTERT protein levels in MCF-7 breast cancer cells.

Beyond the preview

Go deeper on hsa-miR-6752-5p inhibitor.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on hsa-miR-6752-5p inhibitor.

Explore the full profile